Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139581
Status:
COMPLETED
Last Update Posted:
2008-04-23
First Post:
2005-08-30
Brief Title:
Comparison of Pimecrolimus Cream 1 Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Comparison of Pimecrolimus Cream 1 Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is not being conducted in the United States
To investigate the relative efficacy of pimecrolimus cream 1 applied twice daily bid versus once daily od in preventing the progression to disease relapse
To investigate the relative efficacy of pimecrolimus cream 1 applied twice daily bid versus once daily od in preventing the progression to disease relapse
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None